Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma
Robert Jones(Queensland University of Technology), Derek O’Reilly(Manchester Royal Infirmary), Julia Mayerle(LMU Klinikum), Alec McDonald(Beatson West of Scotland Cancer Centre), Stephen Falk(At Bristol), Jonathan Wadsley(Weston Park Cancer Centre), Kinnari Patel(Churchill Hospital), Richard Jackson(University of Liverpool), David Sherriff(Clinical Trial Investigators), Paula Ghaneh(University of Liverpool), Rubin Soomal, Daniel H. Palmer(University of Liverpool), Olusola Olusesan Faluyi(Clatterbridge Cancer Centre NHS Foundation Trust), Roopinder Gillmore, Markus W. Büchler(Heidelberg University), Gary Middleton(University Hospitals Birmingham NHS Foundation Trust), Jakob R. Izbicki(Universität Hamburg), John P. Neoptolemos(University of Liverpool), Christine Tjaden(Heidelberg University), David Cunningham(Royal Marsden NHS Foundation Trust), Bengt Glimelius(Uppsala University), Oliver Strobel(Medical University of Vienna), Tim Meyer(The Royal Free Hospital), Yuk Ting(University Hospitals Birmingham NHS Foundation Trust), Harpreet Wasan(Hammersmith Hospital), Tom Crosby(Southampton General Hospital), Pascal Hammel(Hôpital Paul-Brousse), Juan W. Valle(Cancer Research UK Manchester Institute), Alan Anthoney(St James's University Hospital), Christopher Halloran(University of Liverpool), Paul J. Ross(King's College Hospital NHS Foundation Trust), David Borg(Skåne University Hospital), Suzanne Darby(Weston Park Cancer Centre), Markus M. Lerch(Ludwig-Maximilians-Universität München), Fiona Campbell(University of Birmingham), Pehr Lind(Karolinska Institutet), Sharmila Sothi(University Hospital Coventry), Sebastian Cummins(National Health Service), Thilo Hackert(Universität Hamburg), Eftychia‐Eirini Psarelli(University of Liverpool)
Cited by 282
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k